Mainstream

Mabylon ag raises chf 30 million to advance peanut allergy lead program my006 to clinical proof of concept

Mabylon AG Raises CHF 30 Million to Advance Peanut Allergy Lead Program MY006 to Clinical Proof-of-Concept

Mabylon AG Raises CHF 30 Million to Advance Peanut Allergy Lead Program MY006 to Clinical Proof-of-Concept

Funding combines equity investment and convertible loan Focus on best-in-class, clinical-stage peanut allergen neutralizing…Read More

You might also be interested in reading NerdWallet GAAP EPS of $0.11 beats by $0.01, revenue of $186.9M misses by $8.42M.

August 12, 2025
In Mainstream